Virucidal Effect of Povidone Iodine on SARS-CoV-2 in Nasopharynx: An Open-label Randomized Clinical Trial

Mostafa Kamal Arefin, Sultana Sahana Banu, A K M Nasir Uddin, S K Nurul Fattah Rumi, Mala Khan, Ahsanul Kaiser, Muhammad Shaharior Arafat, Joybaer Anam Chowdhury, Md Abdullah Saeed Khan, Mohammad Jahid Hasan, Mostafa Kamal Arefin, Sultana Sahana Banu, A K M Nasir Uddin, S K Nurul Fattah Rumi, Mala Khan, Ahsanul Kaiser, Muhammad Shaharior Arafat, Joybaer Anam Chowdhury, Md Abdullah Saeed Khan, Mohammad Jahid Hasan

Abstract

To assess the virucidal effect of povidone iodine (PVP-I) on severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) located in the nasopharynx and suitable dose-formulation for nasal application were the purpose of this clinical trial. This single-center, open-label randomized clinical trial with a 7-arm parallel-group design was conducted in Dhaka Medical College (DMC) Hospital. A total of 189 reverse transcription-polymerase chain reaction (RT-PCR)-confirmed SARS CoV-2 positive cases aged 12-90 years with symptoms was sequentially enrolled following randomization. Nasopharyngeal clearance of SARS-CoV-2 was tested against PVP-I nasal irrigation (NI) at diluted concentrations of 0.4%, 0.5% and 0.6%, and PVP-I nasal spray (NS) at diluted concentrations of 0.5% and 0.6%. All groups were compared to the corresponding controls (distilled water). Written informed consent was ensured before participation. All procedures were conducted in after ethical clearance from the Ethical Review Board and in accordance with the Declaration of Helsinki. Viral clearance in a repeat RT-PCR (qualitative) was the primary outcome, and occurrence of any adverse event following administration of testing drug was considered as the secondary outcome. Analysis was performed using SPSS (Version 26). All cases were randomized into seven groups and each group consists of 27-patient. Mean age of the cases 43.98 ± 12.67 years (SD). All strength of NI were effective in nasopharyngeal clearance compared to the control (0.4%, p = 0.006; 0.5%, p < 0.001; and 0.6%, p = 0.018). Similarly, all strength of the NS is also effective than control (0.5%, p = < 0.001; and 0.6%, p ≤ 0.001). Highest nasopharyngeal clearance was observed in patients using 0.5% NI (n = 25, 92.6%, p = 0.018). Nasal irritation was the single most adverse event recorded in this trial and found in two patients using 0.4%, and 0.6% PVP-I NI, respectively. Both PVP-I NS and NI are effective for nasopharyngeal clearance in-vivo. However, further community trials are needed to repurpose these solutions as preventive agents against SARS-CoV2. Ethical clearance memo no ERC-DMC/ECC/2020/93. Trial registration NCT Identifier number NCT04549376.

Supplementary information: The online version contains supplementary material available at 10.1007/s12070-022-03106-0.

Keywords: COVID-19; Nasal irrigation; Nasal spray; Povidone iodine; Randomized clinical trial.

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interests.

© Association of Otolaryngologists of India 2022.

Figures

Fig. 1
Fig. 1
Proportion of nasopharyngeal clearance after intervention. NI-Nasal irrigation, NS-Nasal spray

References

    1. World Health Organization: WHO (2021) Coronavirus disease (COVID-19) pandemic,
    1. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. doi: 10.1038/s41579-018-0118-9.
    1. Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7.
    1. Gallo O, Locatello LG, Mazzoni A, et al. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 2021;14:305–316. doi: 10.1038/s41385-020-00359-2.
    1. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1175–1177. doi: 10.1056/NEJMc2001737.
    1. Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8:581–593. doi: 10.1007/s40121-019-00260-x.
    1. Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212:119–123. doi: 10.1159/000089211.
    1. Eggers M, Eickmann M, Zorn J. Rapid and effective virucidal activity of povidone-iodine products against middle east respiratory syndrome coronavirus (MERS-CoV) and modified vaccinia virus ankara (MVA) Infect Dis Ther. 2015;4:491–501. doi: 10.1007/s40121-015-0091-9.
    1. Sriwilaijaroen N, Wilairat P, Hiramatsu H, et al. Mechanisms of the action of povidone-iodine against human and avian influenza a viruses: its effects on hemagglutination and sialidase activities. Virol J. 2009;6:1–10. doi: 10.1186/1743-422X-6-124.
    1. Anderson DE, Sivalingam V, Kang AEZ, et al. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9:669–675. doi: 10.1007/s40121-020-00316-3.
    1. Lamas LM, Dios PD, Rodríguez MT et al (2020) Is povidone‐iodine mouthwash effective against SARS‐CoV‐2? First in vivo tests. Oral Diseases
    1. Guenezan J, Garcia M, Strasters D, et al. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19. JAMA Otolaryngol Neck Surg. 2021 doi: 10.1001/jamaoto.2020.5490.
    1. Juszczak E, Altman DG, Hopewell S, et al. Reporting of multi-arm parallel-group randomized trials. JAMA. 2019;321:1610. doi: 10.1001/jama.2019.3087.
    1. Hasan MJ, Rumi SKNF, Banu SS, et al. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: a structured summary of a study protocol for an open-label randomized clinical trial. Trials. 2021;22:2. doi: 10.1186/s13063-020-04963-2.
    1. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–1179. doi: 10.1056/NEJMc2001737.
    1. Mancuso P, Venturelli F, Vicentini M, et al. Temporal profile and determinants of viral shedding and of viral clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive subjects: a population-based prospective cohort study in Reggio Emilia, Italy. BMJ Open. 2020 doi: 10.1136/bmjopen-2020-040380.
    1. Stathis C, Victoria N, Loomis K, et al. Review of the use of nasal and oral antiseptics during a global pandemic. Future Microbiol. 2021;16:119–130. doi: 10.2217/fmb-2020-0286.
    1. Hassandarvish P, Tiong V, Mohamed NA, et al. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. 2020 doi: 10.1038/s41415-020-2402-0.
    1. Guenezan J, Garcia M, Strasters D, et al. Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19. JAMA Otolaryngol Neck Surg. 2021;9:1871.
    1. Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681–687. doi: 10.1038/s41591-020-0868-6.
    1. Kirk-Bayley J, Challacombe S, Sunkaraneni V, et al. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may protect healthcare workers and reduce cross infection. SSRN Electron J. 2020 doi: 10.2139/ssrn.3563092.
    1. Khan MM, Parab SR, Paranjape M. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic. Am J Otolaryngol. 2020;41:102618. doi: 10.1016/j.amjoto.2020.102618.
    1. Gluck U, Martin U, Bosse B, et al. A clinical study on the tolerability of a liposomal povidone-iodine nasal spray: implications for further development. ORL. 2007;69:92–99. doi: 10.1159/000097758.
    1. Nagata K, Takasu N, Akamine H, et al. Urinary iodine and thyroid antibodies in Okinawa, Yamagata, Hyogo, and Nagano, Japan: the differences in iodine intake do not affect thyroid antibody positivity. Endocr J. 1998;45:797–803. doi: 10.1507/endocrj.45.797.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe